Home/Filings/4/0001818382-24-000165
4//SEC Filing

Sander Dale A. 4

Accession 0001818382-24-000165

CIK 0001818382other

Filed

Aug 28, 8:00 PM ET

Accepted

Aug 29, 6:45 PM ET

Size

9.1 KB

Accession

0001818382-24-000165

Insider Transaction Report

Form 4
Period: 2024-08-27
Sander Dale A.
CFO and Chief Corp. Deve. Off.
Transactions
  • Exercise/Conversion

    Common Stock

    2024-08-27$2.56/sh+39,389$100,83641,389 total
  • Exercise/Conversion

    Stock Options (right to buy)

    2024-08-2739,3890 total
    Exercise: $2.56From: 2018-09-01Exp: 2025-09-01Common Stock (39,389 underlying)
  • Sale

    Common Stock

    2024-08-27$6.68/sh39,389$263,1192,000 total
Holdings
  • Common Stock

    (indirect: By Spouse)
    20,600
Footnotes (1)
  • [F1]The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.67 to $6.725. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Issuer

Humacyte, Inc.

CIK 0001818382

Entity typeother

Related Parties

1
  • filerCIK 0001878193

Filing Metadata

Form type
4
Filed
Aug 28, 8:00 PM ET
Accepted
Aug 29, 6:45 PM ET
Size
9.1 KB